Malarone Paediatric

Atovaquone/proguanil, the active ingredient in Malarone Paediatric, is an antimalarial combination presented as an oral tablet for oral use. It is used to prevent and treat malaria caused by Plasmodium falciparum in children. The combination exploits synergistic mechanisms to provide both prophylactic and therapeutic coverage in pediatric patients traveling to or residing in malaria‑endemic regions.

GNH USA supplies Malarone Paediatric as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams in both public and private health sectors worldwide.

Malarone Paediatric, an antimalarial combination, is indicated for the prevention and treatment of malaria caused by Plasmodium falciparum.

- Prevention of malaria (travel prophylaxis): Provides protective antimalarial activity for children traveling to or residing in endemic areas. - Treatment of acute uncomplicated malaria: Clears Plasmodium falciparum infection in pediatric patients with confirmed malaria. - Post‑exposure prophylaxis: Used after possible exposure to malaria‑infected mosquitoes to prevent disease onset in children.

Malarone Paediatric may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: discomfort in the upper abdomen. - Headache: transient headache episodes. - Diarrhoea: loose stools, usually self‑limiting. - Metallic taste: temporary alteration of taste perception. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hemolytic anaemia: especially in patients with G6PD deficiency. - Severe hypersensitivity: anaphylaxis or angioedema. - Cardiac arrhythmias: rare QT prolongation. - Visual disturbances: blurred vision or eye pain.

Before prescribing Malarone Paediatric, clinicians should consider several safety aspects.

- Weight‑based dosing: dose must be calculated according to the child's weight and age. - Renal or hepatic impairment: adjust therapy and monitor function closely. - G6PD deficiency: assess risk of hemolysis before use. - Concomitant QT‑prolonging drugs: avoid or monitor cardiac rhythm. - Pregnancy and breastfeeding: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Malarone Paediatric can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Rifampicin: reduces plasma concentrations of both components, compromising efficacy. - Cimetidine: may increase atovaquone levels, raising risk of toxicity. - Antiretroviral protease inhibitors (e.g., ritonavir): can significantly lower atovaquone exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: possible increase in serum levels; observe for toxicity. - Other QT‑prolonging agents: monitor ECG for arrhythmias.